Pulmatrix PULM 深 滬
等待開盤 08-29 09:30:00 美东时间
4.96
+0.100
+2.06%
華盛通- 最 高4.9994
- 今 開4.86
- 成交量 1.04万股
- 最 低 4.8563
- 昨 收 4.86
- 總市值 1811.54万
- 52周最高 10.40
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.78
- 委 比 -30.12%
- 總股本 365.23万
- 歷史最高 4235.00
- 量 比 0.80
- 振 幅 2.94%
- 歷史最低 1.55
- 每 手 1
- 風險率 2.12%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pulmatrix Q2 EPS $(0.42) Up From $(1.59) YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.42) per share. This is a 73.58 percent increase over losses of $(1.59) per share from the same period last year.
08-06 20:16
Pulmatrix GAAP EPS of -$0.42
Pulmatrix press release (NASDAQ:PULM): Q2 GAAP EPS of -$0.42. The Company's total cash and cash equivalents balance as of June 30, 2025, was $5.8 million. The Company anticipates that its cash positio...
08-06 20:16
Pulmatrix Seeks Divestment Of Clinical Assets And iSPERSE Inhalation Technology Amid Advancements In Migraine, COPD, And Antifungal Treatments
Pulmatrix Currently Seeking Divestment of Clinical Assets and Proprietary iSPERSE™ TechnologyiSPERSE™ TechnologyiSPERSE™ particles are engineered with a small, dense and dispersible profile to exceed
08-06 20:15
Pulmonx to Present at the Canaccord Genuity 45th Annual Growth Conference
Pulmonx Corporation (Nasdaq: LUNG), a global leader in minimally invasive lung disease treatments, announced it will present at the Canaccord Genuity 45th Annual Growth Conference in Boston on August 12, 2025. The presentation will be available live and archived on the company’s investor website. Pulmonx develops innovative devices like the Zephyr Endobronchial Valve and Chartis Pulmonary Assessment System to treat severe emphysema/COPD. The Zeph...
07-29 20:05
Pulmonx to Report Second Quarter 2025 Financial Results on July 30, 2025
Pulmonx Corporation announced on July 16, 2025, that it will release its second-quarter 2025 financial results after market close on July 30, 2025. A conference call to discuss the results will follow at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast will be available on the Pulmonx investor website. Pulmonx is a global leader in minimally invasive lung disease treatments, offering products like the Zephyr® Endobronchial Valve for emphy...
07-16 20:05
Pulmatrix Stockholders Approve Merger with Cullgen
Pulmatrix ( ($PULM) ) has issued an update. On June 16, 2025, Pulmatrix held a ...
06-17 04:53
Pulmonx to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
Pulmonx Corporation will present at the Goldman Sachs 46th Annual Global Health Care Conference in Miami on June 11, 2025, at 7:00 AM PT / 10:00 AM ET. A live and archived webcast will be available on the Pulmonx website. Pulmonx is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), particularly for patients with severe emphysema. The company's products, including the FDA-approved Zephyr® Endobronch...
05-28 20:05
Pulmatrix GAAP EPS of -$0.50
Pulmatrix press release (NASDAQ:PULM): Q1 GAAP EPS of -$0.50. The Company's total cash and cash equivalents balance as of March 31, 2025, was $7.7 million. The Company anticipates that its cash positi...
05-15 20:24
Pulmatrix Q1 EPS $(0.50) Down From $0.23 YoY
Pulmatrix (NASDAQ:PULM) reported quarterly losses of $(0.50) per share. This is a 317.39 percent decrease over earnings of $0.23 per share from the same period last year.
05-15 20:21
CUMBERLAND PHARMACEUTICALS PARTNERS WITH QUREIGHT TO ADVANCE INNOVATIVE IDIOPATHIC PULMONARY FIBROSIS TREATMENT RESEARCH
Cumberland leveraging Qureight's deep-learning AI platform for its Phase II FIGHTING FIBROSIS™ clinical trial NASHVILLE, Tenn. and CAMBRIDGE, England, May 13, 2025 /PRNewswire/ -- Cumberlan...
05-14 04:05
